IMAGION BIOSYSTEMS

Company Overview

June 2017

www.imagionbiosystems.com

Disclaimer

This presentation has been prepared by Imagion Biosystems Limited (Imagion) in relation to a proposed sale or issue of shares to certain investors who are sophisticated or professional investors and wholesale clients (as those terms are defined in the Corporations Act 2001 (Cth) (Corporations Act).

This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.

This presentation is not a prospectus, product disclosure statement or other disclosure document under Australian law (or any other law), and has not been lodged with the Australian Securities and Investments Commission (or any other regulatory body in Australia or abroad). This presentation is being made available to you on the basis that you are a person to whom a disclosure document is not required under the Corporations Act in order to lawfully receive an offer to subscribe for securities in Imagion.

This presentation contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.
This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.

Currency translation

All figures in this presentation are expressed in US Dollars or where identified as Australian Dollars (AUD or A$) are converted, where relevant, at an exchange rate of [0.75] USD/AUD.

MagSense™ Technology

Revolutionizing Cancer Diagnosis

Optimizing Patient Care and Reducing Mortality Rates through the Early Detection of Cancer

Investment Highlights

$100 Billion

Annual global spending on cancer diagnosis in imaging and pathology

8 Patents

Core technology covered in major markets through to 2029

"Printer & Ink" model

Product includes both the instrument and a diagnostic consumable

Key Collaborations

Pre-clinical partnerships already under way with pre-eminent medical research institutes

$2 Billion

Addressable markets for first cancer targets: breast, prostate, ovarian.

Additional targets being explored.

Platform Technology

Not limited to initial targets or cancer diagnostics.

Other potential opportunities include theranostics and reagents

The Opportunity in Cancer Diagnostics



Market Characteristics

- Large market growing 7% annually
- Imaging makes up the largest proportion
- Early detection significantly reduces mortality rates
- Unmet need for early detection that is reliable, specific and non-invasive

"Early detection in order to improve breast cancer outcome and survival remains the cornerstone of breast cancer control."

WHO breast cancer: prevention and control



Advantages of MagSense™ Technology

Improved Sensitivity

- 1000x more sensitive than current imaging methods.
- Early small tumors (~1mm) not readily detectable with current medical imaging technologies.

Better Patient Experience

- Minimizes need for surgical procedures.
- Does not use ionizing radiation or radioactive tracers.
- Early tumor detection reduces risk of metastases.
- Magnetizing and measuring the nanoparticles takes only a few minutes.


Poor Sensitivity and Non-Specific


Biopsy Procedures are Invasive



Rendering of MagSense™ SQD Clinical Instrument

Human studies have not yet been conducted

Non-invasive

- A low dose of cancer specific nanoparticles are administered by simple intravenous injection.
- The patient is positioned under the detector and the nanoparticles are briefly magnetized and detected.

Specific

- Bio-specific antibodies on the nanoparticles target delivery to specific cancer tumor types, differentiating benign from malignant lesions.
- Ultra-sensitive detector locates only nanoparticles bound to target cells and not circulating nanoparticles.

Competitive Position

Reduced Patient Risks

- MagSense™ technology uses a significantly lower magnetic field than MRI, and a routine examination is completed in minutes.
- Unlike PET or X-ray methods which expose patients to radioactivity, super-paramagnetic nanoparticles are considered biologically safe and applied at a low dose.

Less Expensive

- Unlike most imaging methods, the MagSense™ instrument is relatively inexpensive and does not require a specialized high cost shielded environment.
- The cost of a MagSense™ nanoparticle test will be less expensive than MRI or PET procedures, and directly competitive with more invasive procedures.

Method	MagSense Magnetic Relaxometry	MRI Magnetic Resonance Imaging	PET Positron Emission Tomography	Ultrasound	X-Ray/CT
Detection Threshold	< 1 million cells	millions of cells	N/A	4 billion cells	N/A
Quantitative	Yes	Yes	No	No	No
Specificity	Yes	No	No	No	No

MagSense™ Technology



Magnetizing the particles and measuring the response takes about 3 sec.

- All nanoparticles lose their magnetization (i.e. “relax”) after the low magnetic field is turned off
- A nanoparticle attached to a bio-marked cancer cell will relax more slowly than an unattached particle
- Bio-specific antibodies on the nanoparticles cause the particles to stick to the specific targeted tumor types
- Our ultra-sensitive detectors are able to locate and quantify the relaxation of only the attached nanoparticles

Near-term Addressable Markets – US$2 Billion

Breast Cancer

- Invasion of the regional lymph nodes is an early hallmark of metastatic breast cancer
- Imaging methods are neither sensitive enough nor bio-specific to detect localized nodal spread

US$250M Annual Market

- ~ 1.6 M new breast cancer cases annually
- 15% - 20% Her2+ incidence = 240,000 - 320,000 Her2+ breast cancer cases annually
- Lymph node biopsy costs $2500 - $7000; FNA costs $100 - $250 each; SLNB costs $10K - $15K

Prostate Cancer

- For patients with PSA blood biomarker test, only 30% have cancer
- Grey scale ultrasound has an poor accuracy and low positive predictive value

US$1.5 Billion Annual Market

- 1.1M new prostate cancer cases annually
- 1M biopsies in US alone
- Biopsy cost is $1500 - $6000

Ovarian Cancer

- For patients with persistent elevated CA-125 blood biomarker test
- Trans-vaginal ultrasound has poor sensitivity and high false positives
- 70% mortality for treatment methods initiated post ultrasound detection due to late stage

US$200M Annual Market

- ~ 250,000 new ovarian cancer cases annually
- Transvaginal ultrasound costs an average of $525 (range $250 - $1100)

Market size and information related to incidence and costs are company derived estimates from aggregated sources.

Strategic Relationships

Pre-Clinical Collaborations

Research collaborations are in place with some of the world's pre-eminent cancer medical centers to demonstrate *in vivo* detection of breast, prostate, and ovarian cancer in pre-clinical models.



THE UNIVERSITY OF TEXAS MD Anderson Cancer Center
Making Cancer History®

Weill Cornell Medicine

UNM

Dr. John Hazle
Chairman, Dept Imaging Physics

Ovarian cancer

- ***Presenting 4 posters at 2017 AACR***
- ***2 grants submitted to NIH for computational methods***

Dr. John Babich
Prof. Radiopharmaceutical Sci

Prostate cancer

- ***Instrument installation expected H1 '17***
- ***Grant submitted to the NIH***

Dr. Helen Hathaway
Faculty UNM School of Medicine

Breast cancer

- ***Presented at the 2016 San Antonio Breast Cancer Symposium***
- ***Presenting at 2017 AACR***

Board and Management

Robert Proulx
Chairman & CEO

- Operationally oriented executive
- 25 years experience in life science and medical device product development and commercialization

David Ludvigson
Non Exec Director
CEO Nanomix

- Financial and operating executive
- 35 years experience in pharma, medical device and computer products
- Significant experience in corporate strategy, M&A, and financing

Michael Harsh
Non Exec Director
Founder Terapede Systems

- Former VP & CTO of GE Healthcare's Medical Imaging Business
- 35 years experience in Engineering and product development of medical imaging technologies including MRI, X-ray, and ultra sound

John Hazle PhD
Non Exec Director
Chair Imaging Physics MD Anderson

- Board certified for both therapeutic and diagnostic medical physics
- 30 years experience in pre-clinical and clinical medical imaging research
- Chairs Cancer Research programs at UT Graduate School of Biomedical Sciences

Jovanka Naumoska
Director / Secretary
Business Mgr
ANSTO

- Australian attorney with expertise in regulatory compliance, corporate, governance and risk, general and commercial liability, & intellectual property

Mark Van Asten
Non Exec Director
Founder Diagnostic Technology Pty Ltd

- Australian business executive with strong background in diagnostics and healthcare
- 25 years experience in market development and commercializing diagnostic products

Brian Conn
CFO

- Financial executive with strong background in early and growth stage biotech
- 25 years experience in raising both public and private capital and M&A activities

Giulio Paciotti PhD
VP R&D

- Former CSO at CytImmune Sciences developer of gold nanoparticle therapeutic
- 25 years experience in tumor biology research and cancer related product development

Peter DiChiara
Non Exec Director
Partner Carmel, Milazzo & DiChiara

- 30 years experience on securities issuance, regulatory compliance and corporate governance.
- Licensed as both as an attorney and certified public accountant in the State of New York

IPO/Capital Structure

Imagion lists on the Australian Securities Exchange (ASX) on 21 June 2017

- A$12 million raised as part of IPO
- IPO funds initial commercial product development & achieve first-in-human clinical study

Shares issued to Seed Shareholders		62,183,576
Shares issued to Mason Group		3,333,333
Shares issued to Manhattan Scientifics		64,099,476
Shares issued under the IPO		60,000,000
Shares issued to Lead Manager		14,000,000
Shares issued to Consultants		450,000
Subtotal		**204,066,385**
Rights over Shares issued to Key Management Group (1)		12,100,000
Rights over Shares issued to Employees of Imagion US (2)		2,550,000
Rights over Shares issued to non-executive Directors (3)		900,000
Total Shares		**219,616,385**
Enterprise Value at $0.20 per share		31,929,277
Market Capitalization at $0.20c per share		43,929,277

1) Up to 12,100,000 rights over Shares will be issued to the Key Management Group as an initial grant under the Long Term Incentive Plan, which will vest over 2 years and be subject to certain performance milestones being met.
2) A total of 2,550,000 rights over Shares will be issued to employees of Imagion US under the Long Term Incentive Plan, which will vest quarterly over 2 years, and will not be subject to performance milestones.
3) A total of 900,000 rights over Shares will be issued to non-executive Directors under the Long Term Incentive Plan, which will vest at 2 years after Listing.'

Use of Funds and Timeline



A$3.5m Seed Round Completed 1Q17

$A12m IPO Completed June 2017

$A15m to A$20 from:
Non-dilutive: Collaborations, Licenses, Sale of Nanoparticles
Dilutive: Secondary raising

Milestones and Value Inflection Points

- Clearance by FDA/TGA for "Investigational Use" significantly reduces technical risk – particles and instrument are deemed safe for use in clinical setting
- 1st Clinical study will demonstrate technology value proposition of non-invasive detection of a specific form of cancer and open the path to further studies and expanded uses
- Deal with Commercial Partner or Licensee will include up front commercial rights fee and royalties on product sales



Imagion Biosystems Message Map



IMAGION BIOSYSTEMS

Bob Proulx, President & CEO
Imagion Biosystems
800 Bradbury SE Suite 213
Albuquerque, NM 87106
bob.proulx@imagionbio.com
505-243-1058

Investor Relations
Matt Wright
NWR Communications
matt@nwrcommunications.com.au
+61-451-896-420